Genetics - required/strongly recommended

• HLA-B*5701 positive
• Hypersensitivity risk increased

• Ziagen
• Epzicom (w/ lamivudine)
• Trizivir (w/zidovudine)

• CYP2C19 PM
• Increased CV events
• Requires conversion by CYP2C19 to active form

• HLA-B*1502 positive
• TEN and SJS

• HER2/neu oncogene positive
• CAN USE DRUG

• HER2/neu oncogene positive
• CAN USE DRUG

• HER2/neu oncogene positive
• CAN USE DRUG

• HER2/neu oncogene positive
• CAN USE DRUG

• K-Ras positive
• Not effective in COLON CANCER- DO NOT USE

• EGFR positive
• CAN USE DRUG in non-small cell lung cancer

• K-Ras positive
• Not effective in COLON CANCER- DO NOT USE

• EGFR positive
• CAN USE DRUG in non-small cell lung cancer

• EGFR positive
• CAN USE DRUG in non-small cell lung cancer

• CD117 (KIT, C-Kit) positive
• CAN USE FOR gastrointestinal stromal tumors

• BCR-ABL positive (Philadelphia chromosome)
• CAN USE FOR chronic myelogenous leukemia (CML)

• CCR5 positive
• CAN use drug for HIV

• CXCR4-tropic positive
• DO NOT use for HIV

• BCR-ABL positive (Philadelphia chromosome)
• CAN USE FOR chronic myelogenous leukemia (CML)

• BCR-ABL positive (Philadelphia chromosome)
• CAN USE FOR chronic myelogenous leukemia (CML)

• BCR-ABL positive (Philadelphia chromosome)
• CAN USE FOR chronic myelogenous leukemia (CML)

• BCR-ABL positive (Philadelphia chromosome)
• CAN USE FOR chronic myelogenous leukemia (CML)

• B-Cell CD20 expression positive (main mechanism of action)
• CAN USE drug

• B-Cell CD20 expression positive (main mechanism of action)
• CAN USE drug

• NS3 Q80K positive
• DO NOT USE - will not respond

• Anaplastic Lymphoma kinase (ALK) positive
• CAN USE DRUG

• Anaplastic Lymphoma kinase (ALK) positive
• CAN USE DRUG

• BRAF V600E or V600K positive
• CAN use drug for melanoma

• BRAF V600E or V600K positive
• CAN use drug for melanoma

• BRAF V600E or V600K positive
• CAN use drug for melanoma

• Thiopurine methyltransferase (TPMT) positve for loss of function alelle
• Increased risk of myelosupression 
• Do not use or start at very low dose

Thiopurine methyltransferase (TPMT) positve for loss of function alelleIncreased risk of myelosupression Do not use or start at very low dose

• Thiopurine methyltransferase (TPMT) positve for loss of function alelle
• Increased risk of myelosupression
• Do not use or start at very low dose

• 5q deletion positive
• CAN USE DRUG
• Increased hematologic toxicity, but better therapy response

• MS4A1 (CD-20 antigen) positive
• CAN use
• CD-20 is main MOA

• TNFRSF8 (CD-30 antigen) positive
• CAN USE drug
• Main MOA

• IL2RA (CD-25 antigen) positive
• Can use

Plavix

Tegretol

Herceptin

Kadcyla

Tykerb

Perjeta

Erbitux

Vectibux

Tarceva

Gilotrif

Gleevec

Selzentry

Sprycel

Tasigna

Bosulif

Iclusig

Rituxan

Arzerra

Olysio

Xalkori

Zykadia

Zelboraf

Tafinlar

Mekinist

Revlimid

Adcetris

Ontak